An average of 4,000 people are needed to test a new drug before it can be sold. According to several studies, hundreds of drugs are developed each year, creating intense competition for test subjects. The US & EU are actively involved in Clinical Trials; therefore, the hopes for a widening market are now limited. Each day's delay getting a major drug on the market costs $1.3 million in unrealized sales, according to industry estimates. In this case, Eastern European countries are now more attractive for Western Pharmaceuticals Companies. Several factors influence the decision to conduct phase II & III Clinical Trials in the CEE and CIS regions. The conference will provide a forum for people responsible for managing European clinical trials at the institutional level to discuss and work through the various challenges they face in their work in a supportive environment with peers and colleagues. Particular emphasis will be placed on the practicalities of ensuring patient safety by adhering to Good Clinical Practice (GCP) whilst complying both with “local”, national, and European legislation.
The Scientific Committee